DHL Supply Chain North America is set to acquire SDS Rx, a specialist in final-mile healthcare delivery. The acquisition strengthens DHL’s capabilities in life sciences and healthcare logistics, covering long-term care and specialty pharmacies, radiopharmacies, and health system networks.
SDS Rx operates from over 200 locations across the U.S., adding same-day and expedited delivery services to DHL’s healthcare network. The move enhances DHL’s ability to provide integrated, time-critical solutions across the full healthcare supply chain.
Mark Kunar, CEO of DHL Supply Chain North America, highlighted the growing demand for specialty pharmacy and healthcare solutions. “This acquisition allows us to expand our healthcare logistics capabilities and serve new segments of customers while reinforcing our position as a trusted partner,” he said.
Drew Kronick, CEO of SDS Rx, emphasized the shared focus on patient care. “Partnering with DHL combines our strengths to improve the precision, reliability, and speed of delivery to patients most in need,” he said.
This is DHL Supply Chain’s second healthcare acquisition in 2025, following its purchase of CryoPDP earlier this year. The integration of SDS Rx will bring all employees into DHL’s North American Life Sciences & Healthcare business, ensuring a seamless transition for customers and staff.
The acquisition is subject to regulatory approvals.
